Barriers to Vaccination Among People with Parkinson's Disease and Implications for COVID-19.
Aged
Aged, 80 and over
COVID-19
/ prevention & control
Cross-Sectional Studies
Facilities and Services Utilization
/ statistics & numerical data
Female
Health Knowledge, Attitudes, Practice
Health Services Accessibility
/ statistics & numerical data
Humans
Influenza Vaccines
Male
Mobility Limitation
Parkinson Disease
Patient Acceptance of Health Care
/ statistics & numerical data
Pneumococcal Vaccines
United States
Vaccination
/ statistics & numerical data
COVID-19
Parkinson’s disease
Vaccine hesitancy
health services
homebound
influenza
pneumonia
vaccination
Journal
Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362
Informations de publication
Date de publication:
2021
2021
Historique:
pubmed:
4
5
2021
medline:
18
8
2021
entrez:
3
5
2021
Statut:
ppublish
Résumé
Patients with Parkinson's disease (PD) are at higher risk of vaccine-preventable respiratory infections. However, advanced, homebound individuals may have less access to vaccinations. In light of COVID-19, understanding barriers to vaccination in PD may inform strategies to increase vaccine uptake. To identify influenza and pneumococcal vaccination rates, including barriers and facilitators to vaccination, among homebound and ambulatory individuals with PD and related disorders. Cross-sectional US-based study among individuals with PD, aged > 65 years, stratified as homebound or ambulatory. Participants completed semi-structured interviews on vaccination rates and barriers, and healthcare utilization. Among 143 participants, 9.8% had missed all influenza vaccinations in the past 5 years, and 32.2% lacked any pneumococcal vaccination, with no between-group differences. Homebound participants (n = 41) reported difficulty traveling to clinic (p < 0.01) as a vaccination barrier, and despite similar outpatient visit frequencies, had more frequent emergency department visits (31.7% vs. 9.8%, p < 0.01) and hospitalizations (14.6% vs. 2.9%, p = 0.03). Vaccine hesitancy was reported in 35% of participants, vaccine refusal in 19%, and 13.3% reported unvaccinated household members, with no between-group differences. Nearly 13% thought providers recommended against vaccines for PD patients, and 31.5% were unsure of vaccine recommendations in PD. Among a sample of homebound and ambulatory people with PD, many lack age-appropriate immunizations despite ample healthcare utilization. Many participants were unsure whether healthcare providers recommend vaccinations for people with PD. In light of COVID-19, neurologist reinforcement that vaccinations are indicated, safe, and recommended may be beneficial.
Sections du résumé
BACKGROUND
Patients with Parkinson's disease (PD) are at higher risk of vaccine-preventable respiratory infections. However, advanced, homebound individuals may have less access to vaccinations. In light of COVID-19, understanding barriers to vaccination in PD may inform strategies to increase vaccine uptake.
OBJECTIVE
To identify influenza and pneumococcal vaccination rates, including barriers and facilitators to vaccination, among homebound and ambulatory individuals with PD and related disorders.
METHODS
Cross-sectional US-based study among individuals with PD, aged > 65 years, stratified as homebound or ambulatory. Participants completed semi-structured interviews on vaccination rates and barriers, and healthcare utilization.
RESULTS
Among 143 participants, 9.8% had missed all influenza vaccinations in the past 5 years, and 32.2% lacked any pneumococcal vaccination, with no between-group differences. Homebound participants (n = 41) reported difficulty traveling to clinic (p < 0.01) as a vaccination barrier, and despite similar outpatient visit frequencies, had more frequent emergency department visits (31.7% vs. 9.8%, p < 0.01) and hospitalizations (14.6% vs. 2.9%, p = 0.03). Vaccine hesitancy was reported in 35% of participants, vaccine refusal in 19%, and 13.3% reported unvaccinated household members, with no between-group differences. Nearly 13% thought providers recommended against vaccines for PD patients, and 31.5% were unsure of vaccine recommendations in PD.
CONCLUSION
Among a sample of homebound and ambulatory people with PD, many lack age-appropriate immunizations despite ample healthcare utilization. Many participants were unsure whether healthcare providers recommend vaccinations for people with PD. In light of COVID-19, neurologist reinforcement that vaccinations are indicated, safe, and recommended may be beneficial.
Identifiants
pubmed: 33935103
pii: JPD202497
doi: 10.3233/JPD-202497
pmc: PMC8355058
mid: NIHMS1701902
doi:
Substances chimiques
Influenza Vaccines
0
Pneumococcal Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1057-1065Subventions
Organisme : NINDS NIH HHS
ID : U01 NS100610
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066512
Pays : United States
Organisme : NIA NIH HHS
ID : R24 AG063725
Pays : United States
Organisme : NINDS NIH HHS
ID : K23 NS097615
Pays : United States
Organisme : NIA NIH HHS
ID : U54 AG063546
Pays : United States
Organisme : NCCIH NIH HHS
ID : UG3 AT009844
Pays : United States
Organisme : NINR NIH HHS
ID : R01 NR016461
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG054574
Pays : United States
Organisme : NIA NIH HHS
ID : R33 AG057291
Pays : United States
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Ann Intern Med. 2020 Dec 15;173(12):964-973
pubmed: 32886525
Clin Geriatr Med. 2016 Aug;32(3):609-25
pubmed: 27394026
J Eval Clin Pract. 2021 Apr;27(2):223-227
pubmed: 32754960
J Neurol. 2021 Apr;268(4):1179-1187
pubmed: 32880722
MMWR Morb Mortal Wkly Rep. 2019 Oct 25;68(42):937-942
pubmed: 31647786
PLoS One. 2012;7(7):e39496
pubmed: 22808039
J Am Geriatr Soc. 2018 Jul;66(6):1226-1232
pubmed: 29608779
Neurol Clin Pract. 2020 Aug;10(4):277-286
pubmed: 32983607
BMC Public Health. 2018 Jul 16;18(1):885
pubmed: 30012141
Eur J Epidemiol. 2020 Aug;35(8):775-779
pubmed: 32785815
Eur J Epidemiol. 2020 Apr;35(4):325-330
pubmed: 32318915
J Am Geriatr Soc. 2010 Dec;58(12):2423-8
pubmed: 21070195
Virus Res. 2020 Oct 15;288:198114
pubmed: 32800805
J Am Geriatr Soc. 2020 May;68(5):926-929
pubmed: 32255507
Int Rev Neurobiol. 2017;132:33-54
pubmed: 28554413
Am J Prev Med. 2015 Dec;49(6 Suppl 4):S383-90
pubmed: 26590438
Parkinsonism Relat Disord. 2013 Nov;19(11):949-54
pubmed: 23835430
Mov Disord. 2018 Apr;33(4):537-543
pubmed: 29356127
J Parkinsons Dis. 2020;10(4):1365-1377
pubmed: 32925107
Vaccine. 2017 Apr 25;35(18):2315-2328
pubmed: 28343775
J Parkinsons Dis. 2021;11(1):3-8
pubmed: 33523021
Mov Disord. 2020 Jul;35(7):1089-1093
pubmed: 32484584
Influenza Other Respir Viruses. 2018 Nov;12(6):808-813
pubmed: 30028081
Gerontologist. 2020 Jan 24;60(1):101-111
pubmed: 30864658
J Am Med Dir Assoc. 2021 Feb;22(2):440-445.e2
pubmed: 32723531
Lancet Neurol. 2020 Jul;19(7):623-634
pubmed: 32464101
Vaccine. 2015 Nov 27;33 Suppl 4:D114-20
pubmed: 26615170
Parkinsonism Relat Disord. 2020 Jun;75:91-96
pubmed: 32505085
NPJ Parkinsons Dis. 2020 Jul 9;6:15
pubmed: 32665974
J Parkinsons Dis. 2020;10(s1):S75-S83
pubmed: 32568114
MMWR Morb Mortal Wkly Rep. 2017 Jul 14;66(27):728-733
pubmed: 28704347
Neurology. 2015 Aug 4;85(5):413-9
pubmed: 26138947
Lancet. 2015 Aug 29;386(9996):896-912
pubmed: 25904081
J Parkinsons Dis. 2020;10(4):1355-1364
pubmed: 32925108
J Am Geriatr Soc. 1994 Jun;42(6):630-8
pubmed: 8201149
Cochrane Database Syst Rev. 2018 May 30;5:CD005188
pubmed: 29845606
CMAJ. 2000 Feb 22;162(4):497-500
pubmed: 10701382
Hum Vaccin Immunother. 2019;15(4):863-872
pubmed: 30633706
Clin Interv Aging. 2019 Jul 31;14:1371-1377
pubmed: 31534322
Mov Disord. 2006 Apr;21(4):446-55
pubmed: 16161155
Viruses. 2020 Aug 07;12(8):
pubmed: 32784685
Lancet Infect Dis. 2020 Jul;20(7):769-770
pubmed: 32445713